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Abstract
Background: Invasion is an important early step of cancer metastasis that is not well understood.
Developing therapeutics to limit metastasis requires the identification and validation of candidate
proteins necessary for invasion and migration.
Methods: We developed a functional proteomic screen to identify mediators of tumor cell
invasion. This screen couples Fluorophore Assisted Light Inactivation (FALI) to a scFv antibody
library to systematically inactivate surface proteins expressed by human fibrosarcoma cells
followed by a high-throughput assessment of transwell invasion.
Results: Using this screen, we have identified CD155 (the poliovirus receptor) as a mediator of
tumor cell invasion through its role in migration. Knockdown of CD155 by FALI or by RNAi
resulted in a significant decrease in transwell migration of HT1080 fibrosarcoma cells towards a
serum chemoattractant. CD155 was found to be highly expressed in multiple cancer cell lines and
primary tumors including glioblastoma (GBM). Knockdown of CD155 also decreased migration of
U87MG GBM cells. CD155 is recruited to the leading edge of migrating cells where it colocalizes
with actin and αv-integrin, known mediators of motility and adhesion. Knockdown of CD155 also
altered cellular morphology, resulting in cells that were larger and more elongated than controls
when plated on a Matrigel substrate.
Conclusion: These results implicate a role for CD155 in mediating tumor cell invasion and
migration and suggest that CD155 may contribute to tumorigenesis.
Background
Metastasis is responsible for greater than 90% of cancer-
related deaths [1]. It is therefore of great importance to
develop therapies that limit this process. Cell migration
plays a key role in invasion, an early step in metastasis,
and proteins that regulate migration are often upregulated
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in tumor cells [2]. Cell migration also plays a key role in
the dispersal of tumor cells within a tissue. In glioblast-
oma, the most aggressive form of brain cancer, tumor cells
disperse so extensively that common treatment
approaches such as resection or radiation therapy are not
effective in checking progression [3].
Both invasion and dispersal are complex processes that
require migration of individual cells from the tumor core
into surrounding tissue and the extracellular matrix. Cell
migration requires a coordinated orchestration of com-
plex events including polarization, protrusion, adhesion,
de-adhesion, and retraction [4]. Many cell-surface pro-
teins are involved in regulating migration. Growth factor
receptors receive environmental cues and initiate signal-
ing cascades resulting in polarization and directional
migration [5]. Cell adhesion molecules (CAMs) such as
integrins, cadherins, and immunoglobulin family pro-
teins, mediate adhesion and deadhesion between a cell
and its neighbors or the extracellular matrix (ECM) and
can also contribute to polarization and directional motil-
ity in response to soluble ECM proteins. CAMs sit at the
top of many signaling cascades that regulate actin and
microtubule dynamics through Rho family GTPases [2].
While many proteins have been described to play a role in
cell migration, the mechanisms through which they act
remain unclear [2]. Establishing which of these proteins
are required for tumor invasion and migration is an
important first step to developing therapeutics aimed at
limiting the metastasis or dispersal of tumor cells.
In the post-genome era, global strategies are being devel-
oped to identify new players in complex biological proc-
esses such as tumor cell invasion. Microarray experiments
have identified many differentially expressed genes that
may contribute to enhanced invasion [6-10], but these
correlative expression changes can only suggest functional
importance. RNAi screens for cancer-relevant phenotypes
have already identified several new gene targets [11,12].
Such approaches are limited, however, by the availability
of genome-wide RNAi libraries, the possibility of genetic
compensation following chronic inactivation, and the
inability of RNAi to knockdown stable proteins with slow
turnover. Proteomic screens have the advantage of being
able to assess the proteome in high throughput but do not
directly address function [13].
To complement these approaches, we have developed a
high-throughput, acute protein inactivation strategy
called fluorophore-assisted light inactivation (FALI) that
allows for direct assessment of protein function through
the systematic inactivation of proteins [14-16]. We have
previously applied this approach on a smaller scale to
identify surface proteins important for tumor cell inva-
sion and have established a role for extracellular Hsp90 in
activating metalloproteinases required for invasion [16].
Here we used a larger, unbiased functional proteomic
screen to demonstrate that CD155, the receptor for polio-




HT1080 human fibrosarcoma, Hs27 human fibroblasts,
and U87MG human glioblastoma cells were obtained
from ATCC. Normal human astrocytes were obtained
from Cambrex Bioproducts. Cells were maintained in
DMEM supplemented with 10% fetal bovine serum and
penicillin/streptomycin (Invitrogen; HyClone). HT1080
cells were additionally supplemented with 0.1 mM non-
essential amino acids (Invitrogen). All cells were grown at
37°C under a humidified 7% CO2 atmosphere.
Antibodies
Monoclonal antibodies used for FALI were as follows: β1-
integrin (JB1, Chemicon); CD155 (D171, Neomarkers;
pv404.19, Beckman Coulter). Two additional CD155-spe-
cific monoclonal antibodies (5D11, ID8) were generated
by fusing specific binding scFvs selected from our library
to a human IgG backbone. ScFv 1A2 was used as a nega-
tive control in the migration assay. 1A2 was selected for
binding to the surface of HT1080 cells (see scFv Library
Generation) and was confirmed to bind to the surface of
HT1080 and U87MG cells by immunocytochemistry,
though its protein target is not known. Antibodies used
for immunocytochemistry and immunoblotting were as
follows: CD155 (D171; CD155 rabbit polyclonal, gift of
Dr. Eckard Wimmer); αv-integrin (AB1930, Chemicon);
ErbB2 (06-562, Upstate). Actin was visualized with rhod-
amine-phalloidin (Molecular Probes). Fluorophore-
labeled secondary antibodies were obtained from Molec-
ular Probes; peroxidase-labeled secondary antibodies
were from Cell Signaling.
scFv Library Generation
Spleen RNA was harvested from HT1080 immunized
mice as described [16]. Immunoglobulin cDNA was syn-
thesized using a primer mix and variable regions ampli-
fied using specific primers. Products were cloned into the
phage display vector pXP10 and transfected into E. coli
TG-1 resulting in a library of 107 independent clones.
HTl080-specific scFvs were selected by immunopanning
phage against fixed HT1080 lysate, resulting in 2760
binders. These scFvs were recloned into expression vector
pXP7 (containing his- and E-tags) and expressed in TG-1
cells. Bacterial lysates containing scFv were prepared and
tested for binding to the surface of fixed HT1080 cells by
ELISA. This additional round of selection yielded 595
HT1080 surface binders. These scFvs were confirmed to
bind to the surface of HT1080 by immunocytochemistryBMC Cancer 2004, 4:73 http://www.biomedcentral.com/1471-2407/4/73
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on live cells. For FALI/screening, his-tagged scFvs were
purified from bacterial lysates using Ni-NTA Superflow
resin (Qiagen).
FALI
Antibodies or scFvs were conjugated with FITC (Molecular
Probes) at pH 9.5 at room temperature as previously
described [17]. Cells were detached with Versene (Invitro-
gen) and resuspended in serum-free, phenol red-free
HBSS (Invitrogen). Cells were incubated with FITC-conju-
gated antibodies for 1 h at room temperature with gentle
rocking and were then transferred in at least sextuplet to
replicate clear, flat-bottomed 96-well plates on ice. One
plate was illuminated for 1 h with 300 W (1 × 105 lux)
blue-filtered light (Brilliant Blue #69, Roscolux) using a
high-powered slide projector (Ektagraphic III, Kodak). A
replicate control plate was kept in the dark for 1 h.
Invasion and migration assays
FALI invasion assays with HT1080 cells were done as
described previously [14,16] but used the scFv library
described above. 1 × 105  cells were labeled with cell
tracker orange, incubated with 20 µg/ml of FITC-labeled
scFv, irradiated (or kept in the dark) with blue-filtered
light, and 5 × l04 cells were loaded onto matrigel-coated (4
µg, top) polycarbonate membranes (8 µM, 96-well, Neu-
roprobe). Each sample was assayed in triplicate in at least
two independent experiments. scFvs that showed a signif-
icant change in invasion (p < 0.01 and change > 2 stand-
ard deviations) were assayed a third time with a new scFv
preparation. U87MG and HT1080 migration assays were
performed essentially as above, but excluded matrigel and
used 8µM, 96-well Fluoroblok membranes (BD Bio-
sciences). Cell invasion or migration was quantified using
a fluorescent plate reader (SpectraFluor Plus, Tecan) and
confirmed by visualization under an inverted fluorescent
microscope.
Immunoprecipitation and Mass Spectrometry
To identify scFv protein targets, candidate scFv genes were
re-cloned into expression vector pXP14, containing a
strep-tag. Purified scFvs were coupled to StrepTactin
Sepharose (50 µg/50 µl resin) and the washed scFv-beads
were added to 1 mg HT1080 lysate. The scFv-target com-
plexes were eluted (10 mM D-desthiobiotin, 0.1% Tween
20 in PBS) and the immunoprecipitated proteins were
analyzed by SDS-PAGE and silver staining. In a parallel
experiment, the immunoprecipitated proteins were sub-
jected to deglycosylation using N-glycosidase F prior to
SDS-PAGE analysis. Stained bands were excised and sub-
jected to in-gel tryptic digestion. The peptide fragments
were extracted from the gel, desalted on ZipTip µC18, the
eluted peptides spotted on a Teflon-coated MALDI target,
let dry and overlayed with 1 µl of a 3.5 mg/ml solution of
α-Cyano-hydroxycinnamic acid. The samples were ana-
lyzed on a STR-DE Voyager MALDI mass spectrometer
(Applied Biosystems) and the obtained peptide masses
were used for protein identification via peptide mass fin-
gerprint, searching all entries for the species Homo sapiens
in the NCBI and SwissProt databases. Alternatively, the
extracted peptide fragments were analyzed by nano elec-
trospray mass spectrometry (nanoES-MS) on a Q-STAR
QqTOF mass spectrometer (PE SCIEX). Relevant ions
were selected for CID (collision induced dissociation)-MS
and the obtained fragment ion data used for Peptide
Sequence Tag database search.
CD155 siRNA
A double stranded siRNA oligonucleotide targeting
CD155 (5'-CAACUUUAAUCUGCAACGUdTdT-3') was
chemically synthesized (Dharmacon Research) and trans-
fected into HT1080 cells using Oligofectamine (Invitro-
gen) following manufacturers instructions using 200 nM
siRNA per 10 cm dish. Cells were incubated with siRNA in
OptiMEM (Invitrogen) for 6 hrs after which time normal
growth media was added. Cells were then incubated for
48–72 h to achieve >80% knockdown of CD155. Control
cells were transfected with a scrambled siRNA oligonucle-
otide at matching concentration. Cells were then inserted
into the migration assay described above or used for mor-
phology experiments.
Cell morphology measurements
HT1080 cells were co-transfected with siRNA (scramble
control or CD155-specific) and fluorescently labeled oli-
gonucleotide (10 nM, Sequitur) for 48 hours. Cells were
detached with Versene, and 5–15 × 103 cells were loaded
onto glass coverslips coated with Matrigel (2µg/ml, BD
Biosciences). After 2 hours of incubation at 37°C/7%
CO2, cells were fixed and immunostained for CD155
using mAb D171. Cells were visualized with a Nikon Dia-
phot 200 microscope and images taken of >100 trans-
fected cells (containing fluorescent oligo). Analysis of
images was performed with OpenLab software (Improvi-
sion). Measurements of cell area, perimeter, and shape
were made for each condition.
Wound healing assay
8-chamber slides (Falcon) were coated with matrigel (2
µg/ml) and blocked with FCS. 100,000 cells were plated
in each well and grown to confluency. A 20-gauge needle
was used to create a linear wound and cells allowed to
recover for 3 h at 37°C. Cells were fixed and processed for
immunocytochemistry as described below.
Immunocytochemistry
Cells were fixed in PBS/4% paraformaldehyde/4%
sucrose, blocked in PBS/0.01% triton-x-100/10%FBS, and
incubated in primary antibody for 1 h at rt. Appropriate
species-specific secondary antibodies conjugated to AlexaBMC Cancer 2004, 4:73 http://www.biomedcentral.com/1471-2407/4/73
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488 or 594 were used to visualize antibody staining on a
Leica SP2 confocal microscope using LCS software. Anti-
bodies: CD155 (D171), αv-integrin (AB1930), actin
(rhodamine-phalloidin, Molecular Probes), ErbB2
(6562). Secondary antibodies alone were used to control
for non-specific staining. For primary tissue, paraffin sec-
tions from a human tissue library were stained with bioti-
nylated anti-CD155 human mAb 1D8 at 200 µg/ml and
visualized with streptavidin-hrp and NovaRed substrate.
For glioblastoma tumors, we used tissue microarrays,
made from 20 primary tumors arrayed in quadruplicates
of 1 mm cores with a Beecher Instrument arrayer. Positive
staining was visualized with DAB substrate.
Immunoblotting
Pelleted and PBS-washed cells were lysed in NP40 lysis
buffer (0.2% NP-40, 150 mM NaCl, 20 mM Tris pH7.5,
10% glycerol) with protease inhibitors (Roche) at 4°C.
Lysates were cleared by centrifugation and quantified
using the DC Protein Assay (BioRad). 30 µg lysate was
separated on a 10% SDS-PAGE gel and transferred to a
nitrocellulose membrane. Membranes were blocked in
5% nonfat dry milk in PBS and probed with primary anti-
body overnight. Antibody binding was detected with per-
oxidase-conjugated secondary antibodies (Cell Signaling)
and visualized using ECL substrate (PerkinElmer).
Results
Functional proteomic screen reveals a role for CD155/PVR 
in tumor cell invasion and migration
We generated a recombinant single chain variable fragment
(scFv) antibody library that recognized proteins on the sur-
face of HT1080 fibrosarcoma cells, a highly invasive tumor
cell line. ScFvs were selected from a phage display library
generated from mice immunized with fixed HT1080 cells
[16]. Genes encoding the selected scFvs were re-expressed as
scFv antibodies and selected by ELISA for HT1080 surface
binding. The selected scFvs were conjugated to fluorescein
and used to acutely inactivate their protein targets by fluor-
ophore-assisted light inactivation (FALI). The invasiveness
of FALI- and control-treated cells was then compared using
a 96-well transwell assay incorporating a matrigel-coated
8µM filter above a serum chemoattactant (Fig. 1a). 338
scFvs were screened in triplicate using this FALI-invasion
assay. 15 scFvs caused a significant reduction of invasion
compared to non-FALI controls (p < 0.01, unpaired t-test)
and an amplitude change of greater than twice the average
standard deviation. The majority of scFvs screened (323)
had no significant effect on invasion and serve as an internal
control. The 15 positive scFvs were re-screened using fresh
scFv preparations in triplicate, and six scFvs were selected
that continued to satisfy both criteria of significance (Fig.
1b). Sequencing of the scFv cDNAs revealed two unique
groups of clones. The first group (I) contained a single scFv
binder while the second group (II) included 5 scFvs with
identical or nearly identical variable heavy and light chains.
Protein targets of the two scFv groups were immunoprecip-
itated and identified by mass spectrometry.
The target of group I was α3βl-integrin, a promiscuous
extracellular matrix binder that plays multiple roles in cell
adhesion, morphology, migration, and invasion [18].
Identifying α3βl-integrin demonstrates the ability of our
screen to reveal proteins with a confirmed role in tumor
invasion. The target of group II was CD155, the poliovirus
receptor. CD155 is a member of the nectin subclass of
immunoglobulin domain proteins whose cellular func-
tion has not yet been established. To confirm the identifi-
cation of CD155 as a mediator of invasion, we repeated
the invasion assay using a previously characterized mono-
clonal antibody specific for CD155 (D171). FALI of
CD155 significantly inhibited invasion of HT1080 cells
by 32% (p < 0.01, t-test; Fig. 2a), consistent with the
screening result.
In order to determine whether this result was specific to
invasion through matrigel or due to effects on cell migra-
tion, we repeated the transwell experiment in the absence
of matrigel using several different CD155-specific mono-
clonal antibodies, either previously characterized (D171,
pv404) or newly generated by fusing the variable regions
from our CD155-binding scFvs to a human IgG backbone
(5D11, 1D8). FALI of CD155 significantly inhibited tran-
swell migration by 20 to 23% (p < 0.01, t-test; Fig. 2b),
suggesting a role for CD155 in cell migration that is
responsible for the bulk of its contribution to invasion.
FALI in the absence of antibody or in the presence of scFv
1A2, which had no effect in the invasion screen, did not
alter migration. FALI of CD155 did not affect cellular via-
bility or proliferation (data not shown). FALI with combi-
nations of CD155 binders did not enhance the inhibition
of migration (Fig. 2b), suggesting that inactivation was
maximal or that the antibodies bound and saturated a
common epitope.
To further validate the role of CD155 in tumor cell migra-
tion, we developed a siRNA duplex targeting CD155
mRNA as a complementary, chronic means of protein
inactivation. Knockdown of CD155 mRNA yielded ~90%
depletion of CD155 protein at 72 h and a 23% reduction
in migration compared to control cells transfected with a
scrambled siRNA duplex (p < 0.01, t-test; Fig. 2c). The
extent of migration inhibition due to siRNA was equal to
the inhibition seen by FALI, supporting the specificity of
the antibodies. The observed changes in migration were
not due to changes in survival or proliferation as meas-
ured by an MTS viability assay (data not shown). Taken
together, the results from FALI and siRNA knockdown of
CD155 clearly establish a role for CD155 in tumor cell
invasion and migration.BMC Cancer 2004, 4:73 http://www.biomedcentral.com/1471-2407/4/73
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Proteomic screen reveals a role for CD155 in tumor cell invasion Figure 1
Proteomic screen reveals a role for CD155 in tumor cell invasion. (a) Mice were inoculated with fixed HT1080 cells. 
A phage display library was generated from immunoglobulin genes (VH and VL) to generate recombinant scFvs (107 phage). 
Phage were immunopanned against HT1080 cells, and 2,760 binders were isolated. 595 of the resulting scFvs were further 
selected as HT1080 surface binders. These surface binders were conjugated to FITC and used to inactivate their protein tar-
gets by fluorophore-assisted light inactivation (FALI). The invasiveness of FALI- and control-treated cells was then compared 
using a high-throughput transwell assay in which cells were challenged to invade through a matrigel-coated 8βM filter towards 
a serum chemoattactant. Protein targets of candidate scFvs were identified by immunoprecipitation and mass spectrometry. 
(b) 338 scFvs were screened in triplicate in two independent experiments using the FALI-invasion assay. 6 scFvs caused a sig-
nificant reduction of HT1080 invasion compared to non-FALI controls (p < 0.01, unpaired t-test and an amplitude change of 
greater than twice the average standard deviation).BMC Cancer 2004, 4:73 http://www.biomedcentral.com/1471-2407/4/73
Page 6 of 14
(page number not for citation purposes)
CD155 mediates tumor cell invasion and migration Figure 2
CD155 mediates tumor cell invasion and migration. (a) FALI of CD155 resulted in a significant inhibition of HT1080 
transwell invasion through matrigel towards a serum chemoattractant (∆ invasion ± FALI: no Ab 19 ± 6%; β1-int 32 ± 4%; CD155 
32 ± 11%). (b) FALI of CD155 using multiple mAbs resulted in a significant inhibition of HT1080 transwell migration towards a 
serum chemoattractant (∆ migration ± FALI: no Ab l ± 4%; β1-int 30 ± 6%; 1A2 (control, surface binding scFv) 1 ± 3%; CD155: D171 
23 ± 4%; pv404 20 ± 3%; 5D11 22 ± 4%; 1D8(20) 21± 2%; 1D8(40) 23 ± 4%; CD155pool 22 ± 1%). FALI with CD155 mAb 
pools did not yield greater inhibition, suggesting maximal inactivation or that the binders share a common epitope. (c) CD155-
specific siRNA duplexes were used to knockdown protein expression by about 90% by 72 h. Knockdown of CD155 in HT1080 
cells resulted in a significant decrease in transwell migration compared to control cells transfected with a scrambled duplex (23 
± 4%). * indicates p < 0.01, t-test.BMC Cancer 2004, 4:73 http://www.biomedcentral.com/1471-2407/4/73
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CD155/PVR protein is highly expressed in cancer cells and 
primary tumors compared to normal counterparts
Since our screen was performed using a library selected for
binding to HT1080 surface proteins, and thus might have
a tendency to target proteins upregulated in these cells, we
profiled CD155 expression in these and other cells.
Lysates prepared from normal fibroblasts, fibrosarcoma,
normal astrocytes, and GBM cells were tested for expres-
sion of CD155 by immunoblot using a polyclonal CD155
antibody (gift of Eckard Wimmer).
High levels of CD155 expression were observed in
HT1080 and U87MG cells whereas the protein was only
weakly expressed in their non-tumor counterparts (Fig.
3a). Since HT1080 and U87MG cells are highly invasive
while hs27 cells and normal astrocytes are not (personal
observation), these results suggest that upregulation of
CD155 may contribute to an invasive phenotype.
Given our finding that CD155 appeared to be overex-
pressed in our model tumor cell lines, we evaluated
CD155 expression levels in normal and cancerous human
tissue. We performed immunohistochemistry on paraffin
sections taken from a tissue library using mAb 1D8. In
normal tissue we observed moderate staining in kidney,
plasma cells, liver, lung, theca interna of the ovary, and
testis (data not shown). No staining was observed in nor-
mal adrenal, bladder, brain, breast, colon, heart, pancreas,
placenta, prostate, skin, skeletal muscle, small intestine
epithelium, spleen, stomach, thymus, thyroid, or uterus
(at least two samples examined per tissue). In cancer tis-
sue, we observed extensive staining in a subset of samples
taken from several different tumor types (Fig. 3b). These
included prostate carcinoma (4 out of 10 samples exam-
ined), renal cell carcinoma (4/10), pancreatic carcinoma
(7/10), colon carcinoma (2/10), ovarian carcinoma (2/
10), non-small cell lung carcinoma (1/10), and breast car-
cinoma (1/10). Since CD155 had previously been sug-
gested to be upregulated in glioblastoma (GBM) tumors
[19], we performed immunostaining on a tissue array to
examine CD155 protein expression across twenty differ-
ent GBM tumor samples. Staining was observed in eight of
the samples (Fig. 3c). Two types of positive staining were
evident: scattered positive cells within a predominantly
negative sample (5/20), or diffuse staining across many
cells in the sample (3/20). Collectively, these data indicate
that CD155 expression is frequently elevated in primary
tumors. Since normal and cancerous tissue samples were
not collected from the same patient, we cannot determine
if elevated CD155 expression correlates with tumorigene-
sis, but speculate that such an association may exist.
CD155/PVR is recruited to the leading edge of migrating 
tumor cells and colocalizes with actin and αv-integrin
To address the role of CD155 in migrating cells, we
employed a modified wound-healing assay and examined
the sub-cellular localization of CD155. HT1080 cells were
plated onto chambered tissue culture slides coated with a
thin layer of Matrigel ECM substrate and grown to near con-
fluence. A linear wound was made using a 20-gauge needle
and the cells were allowed to recover for 3 h. Cells were fixed
and immunostained to visualize CD155. CD155 was found
to preferentially localize to the leading edge of cells, though
some staining in trailing edges and cell-cell contacts could
also be seen (Fig. 4a). In cells plated in isolation, where
directionality could not be established, CD155 was consist-
ently observed at some but not all peripheral edges of cells
(data not shown). These results suggest that CD155 is
recruited to the leading edge of migrating cells where it may
be involved in directional motility.
Given our findings that CD155 was important for cell
migration and that it localized to the leading edge of
migrating cells, we asked whether CD155 might co-local-
ize with other proteins known to be involved in motility.
We used immunofluorescence and confocal microscopy
to visualize CD155 along with actin and αv-integrin.
CD155 colocalized extensively with actin ruffles at the
leading edge of migrating cells (Fig. 4b), suggesting a
potential link between CD155 and the actin cytoskeleton.
CD155 also colocalized with αv-integrin, a known medi-
ator of ECM adhesion [20], but not the epidermal growth
factor receptor family member ErbB2, a mediator of
growth factor signaling [21]. Thus, CD155 is associated
with key players in substrate adhesion at the leading edge,
and may be working in concert to mediate motility.
CD155/PVR influences cellular morphology
The previous section showed that CD155 localizes to the
leading edge of migrating cells and colocalizes with
known mediators of motility. Since cell shape changes are
often associated with changes in motility and/or adhe-
sion, we next investigated whether knockdown of CD155
by RNAi affected cellular morphology. HT1080 cells were
transfected with either a CD155-specific or scrambled
control siRNA (200 nM) along with a fluorescent, non-
specific oligo (10 nM) to identify transfected cells. 48
hours after transfection, cells were plated at low density
onto coverslips that had previously been coated with
Matrigel, fixed, and immunostained for CD155 to con-
firm protein knockdown. Only cells containing fluores-
cent oligo were selected for analysis. CD155 knockdown
cells had significantly larger perimeters and appeared
more irregular in shape than control cells (Fig. 5). These
findings suggest that CD155 has a role in cell size and
shape, perhaps by regulating adhesion of cells to their
substrate.BMC Cancer 2004, 4:73 http://www.biomedcentral.com/1471-2407/4/73
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CD155 is highly expressed in cancer cells and primary tumors Figure 3
CD155 is highly expressed in cancer cells and primary tumors. (a) Lysates from normal and cancer-derived cell lines 
were immunoblotted for CD155. CD155 expression was elevated in fibrosarcoma cells (HT1080) vs. normal fibroblasts 
(Hs27) and also in glioblastoma cells (U87MG) vs. normal human astrocytes (NHA). Antibody specificity is demonstrated using 
HT1080 cells in which CD155 expression is knocked down by RNAi. β-actin is shown as a loading control. (b) CD155 protein 
expression was examined by immunocytochemistry across a panel of normal and cancer tissue samples. In normal tissue we 
observed moderate staining in kidney, plasma cells, liver, lung, theca interna of the ovary, and testis. No staining was observed 
in normal adrenal, bladder, brain, breast, colon, heart, pancreas, placenta, prostate, skin, skeletal muscle, small intestine epithe-
lium, spleen, stomach, thymus, thyroid, or uterus. In cancer tissue, significant staining was observed in prostate, renal cell, and 
pancreatic carcinomas as well as in colon, non-small cell lung, ovarian, and breast carcinomas. (c) High CD155 protein expres-
sion was also observed in glioblastoma tumor tissue. Two types of staining were evident: scattered positive cells (arrows) in a 
primarily negative sample, or diffuse staining across many cells in a sample.BMC Cancer 2004, 4:73 http://www.biomedcentral.com/1471-2407/4/73
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CD155 is recruited to the leading edge of migrating cells and colocalizes with actin and αv-integrin Figure 4
CD155 is recruited to the leading edge of migrating cells and colocalizes with actin and αv-integrin. (a) HT1080 
cells were grown to near confluency on a matrigel substrate. A linear wound was made with a 20 g needle and cells allowed to 
recover for 3 h. Cells were fixed and immunostained for CD155. The majority of CD155 appeared to localize to the leading 
edge of migrating cells. (b) CD155 colocalized extensively with actin and αv-integrin at the leading edge of HT1080 cells 
migrating on a matrigel substrate. CD155 did not appear to colocalize with the growth-factor receptor ErbB2.BMC Cancer 2004, 4:73 http://www.biomedcentral.com/1471-2407/4/73
Page 10 of 14
(page number not for citation purposes)
CD155 regulates cellular morphology Figure 5
CD155 regulates cellular morphology. HT1080 cells were transfected with siRNA targeting CD155 or with a scrambled 
control duplex and plated on matrigel after 48 h. Cells were fixed and immunostained for CD155 expression before images 
were acquired for morphometric analysis. (a) Schematic showing measurement parameters. (b) Chang plot showing cell 
perimeter measurements. Perimeters values are expressed as percent of the average control perimeter. As a population, 
CD155 knockdown cells (dark circles) exhibited a significant increase in perimeter compared to controls (light circles). (c) 
Chang plot showing cell shape measurements. Cell shape was defined using the equation (4 × cell area) / cell perimeter2, where 
1 indicates a perfect circle and smaller values indicate a more irregular shape. CD155 knockdown cells (dark circles) were 
more irregular in shape than scrambled controls (light circles). Perimeter: ∆ avg = +18%; shape: ∆ avg = -13%;p < 0.001, t-test; n 
= 120 scramble siRNA and 112 CD155 siRNA.BMC Cancer 2004, 4:73 http://www.biomedcentral.com/1471-2407/4/73
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CD155/PVR regulates migration of glioblastoma cells
Our studies so far have been conducted using HT1080 fib-
rosarcoma cells. To assess the generality of CD155 func-
tion in cancer, we asked whether it could regulate the
migration of other tumor cells in vitro. Our expression
studies suggested that CD155 was upregulated in a subset
of glioblastoma (GBM) tumors for which migratory
behavior is poorly understood [3]. U87MG GBM cells
were found to express high levels of CD155 (Fig. 3a).
Knockdown of CD155 protein by FALI in U87MG cells
resulted in a significant (16 to 22%) decrease in transwell
migration towards a serum chemoattractant (p < 0.01, t-
test; Fig. 6). FALI in the absence of antibody or in the pres-
ence of scFv 1A2, which binds to the surface of U87MG
cells, did not alter migration. Cellular viability and prolif-
eration were unchanged (data not shown). These results
were consistently reproduced using multiple independent
monoclonal antibodies targeting CD155 (D171, pv404,
5D11, 1D8). FALI with combinations of these antibodies
did not enhance the inhibition of migration (Fig. 6), sim-
ilar to our observations in HT1080 cells. These results
demonstrate a role for CD155 in regulating migration
across multiple tumor cell types.
Discussion
We developed a functional proteomic screen to identify
surface proteins involved in tumor cell invasion [16] and
here have expanded it to interrogate a library of 338 single
chain phage display antibodies. One of the proteins iden-
tified as a mediator of invasion was CD155, the poliovirus
receptor. This work reveals a novel role for CD155 as a
CD155 mediates motility of GBM cells Figure 6
CD155 mediates motility of GBM cells. FALI of CD155 using multiple mAbs resulted in a significant inhibition of U87MG 
GBM cell transwell migration towards a serum chemoattractant (no Ab 3 ± 3%; β1-int 47 ± 3%; 1A2 (control, surface binding scFv) 
3 ± 2%; CD155: D171 17 ± 2%; pv404 22 ± 2%; 5D11 16 ± 3%; IDS 17 ± 2%; CD155pool21 ± 4%; * indicates p < 0.01, t-test). 
FALI with CD155 mAb pools did not yield greater inhibition, suggesting maximal inactivation or a common binding site.BMC Cancer 2004, 4:73 http://www.biomedcentral.com/1471-2407/4/73
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mediator of tumor invasion that is likely due to its func-
tion in cell migration.
Knockdown of CD155 by FALI or by RNAi resulted in
impaired in vitro migration and a pronounced change in
cellular morphology with cells becoming more elongated
and irregular in shape. CD155 localizes to the leading
edge of migrating tumor cells and co-localizes with actin
ruffles and αv-integrin, suggesting that CD155 may act in
motility and/or cell-substrate adhesion. We also observed
elevated expression of CD155 in a number of different
cancer cell lines and primary tumors, suggesting a link
between CD155 and tumorigenesis.
The endogenous function of CD155 is not well under-
stood. CD155 is a type I transmembrane glycoprotein first
identified based on its ability to mediate the binding of
poliovirus to host cells [22]. It is a member of the immu-
noglobulin (Ig) superfamily and belongs to a subclass
that contains three Ig-like domains (V-C2-C2). This sub-
class includes the nectins and several nectin-like proteins
including the rodent Tage4 gene [23]. Nectins have been
implicated in organizing cell-adherens junctions through
homo-and heterophillic adhesion [24,25]. While nectins
bind to the actin cytoskeleton through afadin, CD155
does not [24], suggesting that CD155's cellular role is dis-
tinct from that of nectins.
Several proteins have been found to interact with CD155.
The ECM protein vitronectin binds CD155 in vitro sug-
gesting that CD155 may mediate cell-substrate adhesion
[26]. Our findings that CD155 co-localizes with αv-
integrin, a receptor for numerous ECM proteins including
vitronectin, is consistent with previous reports [23] and
suggests a functional role for CD155 in mediating adhe-
sion. Activation of integrins leads to assembly of focal
adhesion complexes that stabilize cellular interaction
with its substrate through intracellular signaling and rear-
rangement of the actin cytoskeleton [27]. Our experi-
ments showed that loss of CD155 inhibited migration
and induced cell spreading. This phenotype is similar to
that observed in F397-FAK fibroblasts in which focal
adhesions are enhanced and cell spreading is increased
[28]. We speculate that CD155 could be involved in mod-
ulating integrin/substrate interactions leading to
decreased adhesion or increased turnover of focal
adhesions. Another Ig-domain containing protein, CD47,
has been shown to bind to αv-integrin and is present in
early adhesion complexes at the leading edge of spreading
melanoma and human vascular endothelial (HUVEC)
cells [29]. CD47 appears to regulate integrin activation
and contribute to integrin-mediated adhesion events [30].
CD155 has also been shown to interact with nectin-3
[23], the dynein motor protein Tctex-1 [31], and also to
reside proximal to CD44 [32]. Future studies will address
the importance of these interactions for cancer cell
migration.
Our results, in which CD155 inhibition reduces migra-
tion, are also consistent with a model in which transient
interactions between CD155 and ECM result in pro-
migratory signals. For example, it is known that binding
of integrins to ECM proteins induces pro-migratory
signaling through clustering of associated kinases [33].
CD155 itself may transduce signals when bound to ECM
proteins or could be involved in the clustering of larger
complexes. During preparation of this manuscript, Oda et
al. reported that crosslinking of exogenously expressed
CD155 resulted in tyrosine phosphorylation of its cyto-
plasmic tail, and concurrent reductions in focal adhesion
kinase (FAK) and paxillin phosphorylation in NIH3T3
mouse fibroblasts [34]. Crosslinking of CD155 also
resulted in decreased adhesion to fibronectin, a reduction
in the number of focal adhesions, and an increase in
migration [34]. It is possible that overexpression of
CD155 in cancer cells drives dimerization of CD155 in
the absence of ligand, resulting in decreased adhesion and
increased migration as well as other signaling events.
CD155 expression has been reported widely to be
restricted to primates [35,36], but recent work suggests
that Tage4 may be a rodent ortholog [37,38]. At the
amino acid level, Tage4 shares only 42% homology with
CD155 [38] and rodents are not susceptible to polio virus
infection [22,39]. However, Tage4 shares the extracellular
structure of CD155 and the two genes reside in syntenic
chromosomal regions [38]. Emerging data suggest func-
tional similarities between the two proteins. Tage4 has
been shown to bind to both nectin-3 and vitronectin
[37,38] and also appears to colocalize with αvβ3-integrin
[37]. Recently, Tage4 has been implicated in cell migra-
tion [37]. Overexpression of Tage4 led to increased migra-
tion of murine L cells in a serum- and integrin-dependent
manner while Tage4 mutants inhibited motility [37]. Fur-
thermore, V12Ras-transformed NIH3T3 cells, which form
tumor nodules in the lungs of nude mice, were found to
express elevated levels of Tage4 and expression of a dom-
inant-negative Tage4 inhibited the ability of these cells to
form nodules [37]. Due to low sequence conservation and
the lack of functional data for CD155, it has been difficult
to resolve whether Tage4 and CD155 are true orthologs.
Our identification of a role for CD155 in tumor cell
migration supports the idea that these proteins are
functionally related. Thus, it will be interesting to com-
pare the two proteins in future studies in order to better
define the mechanism of action for CD155 both in nor-
mal cells and in cancer states.
We observed high levels of CD155 protein expression in a
subset of several different types of primary tumor.BMC Cancer 2004, 4:73 http://www.biomedcentral.com/1471-2407/4/73
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Previously, expression of the CD155 gene had been
reported to be upregulated in colon cancer [40] and pos-
sibly glioblastoma [19]. Here we have extended that
observation at the protein level to several additional
tumor types, including cancers of the prostate, kidney,
pancreas, lung, ovary, breast, and brain, suggesting a
much broader role for CD155 in tumorigenesis. A search
of the EST and SAGE library databases maintained by the
Cancer Genome Anatomy Project (CGAP; http://
cgap.nci.nih.gov) using the unique identifier AACCAC-
CCAG supports the idea that expression of the CD155
gene may be elevated in several tumor types including
colon, brain, kidney, pancreas, lung, and stomach (Table
1). Our finding that CD155 is involved in tumor cell
migration in fibrosarcoma and glioblastoma cells impli-
cates CD155 as a mediator of metastasis and dispersal.
The selective expression of CD155 in tumors compared to
normal tissue further supports the idea that targeted inhi-
bition of CD155 could serve as a useful therapeutic
approach to limit the spread of tumor cells in vivo. Very
recently, Ochiai et al. reported that CD155 expression is
upregulated in several breast cancer cell lines and primary
breast tumors and demonstrated that an oncolytic polio-
virus recombinant delivering a toxic payload could selec-
tively kill breast cancer cells [41]. Our findings suggest
that such a therapeutic approach could also have value in
treating other cancer types. Since elevated expression of
CD155 was detected in a subset of samples from the
examined tumor types, it is possible that CD155 expres-
sion may represent a late-stage event in tumorigenesis. It
is also possible that CD155 could lie in one of several dif-
ferent oncogenic pathways. Further research is necessary
to determine if and how CD155 contributes to cancer pro-
gression in vivo.
This work extends the utility of our FALI-based functional
screening approach in identifying proteins with a role in
tumor cell invasion. Our previous screen identified an
extracellular role for Hsp90 in regulating tumor cell inva-
sion through regulation of MMP2 activity [16]. In con-
trast, this screen has identified a role for CD155 in
regulating tumor cell motility. Thus, our approach can
yield novel mediators of tumor cell invasion that are
involved either directly in invasion or more generally in
cell migration. Future applications of this technology will
likely yield additional validated targets and open new ave-
nues for research.
Conclusions
In summary, we have applied a novel, functional pro-
teomic approach to identify proteins that mediate tumor
cell invasion and have identified a novel role for CD155
in regulating cancer cell invasion and migration. We sug-
gest that CD155 may control migration by regulating cell-
substrate adhesion. We have further shown that CD155 is
commonly expressed at high levels in primary tumors and
speculate that it may contribute directly to tumorigenesis
by enhancing cancer cell migration in vivo.
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